The impact of drug-resistant cytomegalovirus in pediatric allogeneic hematopoietic cell transplant recipients: a prospective monitoring of UL97 and UL54 gene mutations
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Choi, S. -H. | - |
dc.contributor.author | Hwang, J. -Y. | - |
dc.contributor.author | Park, K. -S. | - |
dc.contributor.author | Kim, Y. | - |
dc.contributor.author | Lee, S. H. | - |
dc.contributor.author | Yoo, K. H. | - |
dc.contributor.author | Kang, E. -S. | - |
dc.contributor.author | Ahn, J. -H. | - |
dc.contributor.author | Sung, K. W. | - |
dc.contributor.author | Koo, H. H. | - |
dc.contributor.author | Kim, Y. -J. | - |
dc.date.accessioned | 2021-09-05T02:23:20Z | - |
dc.date.available | 2021-09-05T02:23:20Z | - |
dc.date.created | 2021-06-15 | - |
dc.date.issued | 2014-12 | - |
dc.identifier.issn | 1398-2273 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/96584 | - |
dc.description.abstract | BackgroundCytomegalovirus (CMV) infection is a major cause of morbidity in allogeneic hematopoietic cell transplant (alloHCT) recipients. Little is known about the epidemiology of antiviral resistance in the pediatric population. We performed the prospective study to assess the impact of drug-resistant CMV infections in pediatric alloHCT recipients. MethodsPediatric alloHCT recipients who developed CMV infection were consecutively enrolled from May 2009 to April 2012. CMV polymerase chain reaction amplification and sequencing analysis for UL97 and UL54 genes were performed at enrollment and during follow-up. ResultsIn total, 208 sequence data from viruses in 49 recipients were eligible for the final analysis. Resistant CMV infection caused by UL97 and UL54 mutations occurred in 4.1% (2/49) and 2.0% (1/49), respectively. Known UL97 mutations, M460V and C592G, were observed in each of 2 patients. One patient with the M460V UL97 mutation had an additional T700A UL54 mutation. Drug-resistant CMV attributable mortality was 2.0% (1/49). One or more known sequence variants (drug-sensitive) were observed in all 49 patients. Thirty-one (63.3%) and 28 patients (60.9%) already had known UL97 and UL54 sequence variants before antiviral therapy, respectively. ConclusionThis study provides comprehensive information on the epidemiology of both UL97 and UL54 variants and mutations in alloHCT recipients. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | WILEY | - |
dc.subject | INFECTIOUS COMPLICATIONS | - |
dc.subject | GANCICLOVIR RESISTANCE | - |
dc.subject | RISK-FACTORS | - |
dc.subject | VALGANCICLOVIR | - |
dc.subject | ALEMTUZUMAB | - |
dc.subject | DISEASE | - |
dc.subject | ANTIGENEMIA | - |
dc.subject | GUIDELINES | - |
dc.subject | EMERGENCE | - |
dc.subject | THERAPY | - |
dc.title | The impact of drug-resistant cytomegalovirus in pediatric allogeneic hematopoietic cell transplant recipients: a prospective monitoring of UL97 and UL54 gene mutations | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Hwang, J. -Y. | - |
dc.identifier.doi | 10.1111/tid.12311 | - |
dc.identifier.scopusid | 2-s2.0-84920147973 | - |
dc.identifier.wosid | 000346786400007 | - |
dc.identifier.bibliographicCitation | TRANSPLANT INFECTIOUS DISEASE, v.16, no.6, pp.919 - 929 | - |
dc.relation.isPartOf | TRANSPLANT INFECTIOUS DISEASE | - |
dc.citation.title | TRANSPLANT INFECTIOUS DISEASE | - |
dc.citation.volume | 16 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 919 | - |
dc.citation.endPage | 929 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Immunology | - |
dc.relation.journalResearchArea | Infectious Diseases | - |
dc.relation.journalResearchArea | Transplantation | - |
dc.relation.journalWebOfScienceCategory | Immunology | - |
dc.relation.journalWebOfScienceCategory | Infectious Diseases | - |
dc.relation.journalWebOfScienceCategory | Transplantation | - |
dc.subject.keywordPlus | INFECTIOUS COMPLICATIONS | - |
dc.subject.keywordPlus | GANCICLOVIR RESISTANCE | - |
dc.subject.keywordPlus | RISK-FACTORS | - |
dc.subject.keywordPlus | VALGANCICLOVIR | - |
dc.subject.keywordPlus | ALEMTUZUMAB | - |
dc.subject.keywordPlus | DISEASE | - |
dc.subject.keywordPlus | ANTIGENEMIA | - |
dc.subject.keywordPlus | GUIDELINES | - |
dc.subject.keywordPlus | EMERGENCE | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordAuthor | cytomegalovirus | - |
dc.subject.keywordAuthor | drug resistance | - |
dc.subject.keywordAuthor | ganciclovir kinase | - |
dc.subject.keywordAuthor | UL54 protein | - |
dc.subject.keywordAuthor | hematopoietic stem cell transplantation | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.